Empowered Patient Podcast

Dr. Kumar Dharmarajan, cardiologist and geriatrician and Co-Founder and Chief Medical Officer at World Class Health, is  bringing concierge healthcare to employees of self-insured companies.   The platform includes a global network of top-tier doctors and nurse navigators. Directly negotiating with providers reduces costs and reduces administrative and financial friction for patients seeking planned procedures. The model also reduces friction for physicians by providing them with complete patient records and ensuring prompt payment.

Kumar explains, "We are a global, medically led center of excellence platform. So, by that, we have top doctors and top hospitals around the world, incl...

Dr. Kumar Dharmarajan, cardiologist and geriatrician and Co-Founder and Chief Medical Officer at World Class Health, is  bringing concierge healthcare to employees of self-insured companies.   The platform includes a global network of top-tier doctors and nurse navigators. Directly negotiating with providers reduces costs and reduces administrative and financial friction for patients seeking planned procedures. The model also reduces friction for physicians by providing them with complete patient records and ensuring prompt payment.

Kumar explains, "We are a global, medically led center of excellence platform. So, by that, we have top doctors and top hospitals around the world, incl...

Brent Dial, Founder and CEO of Beek Health, has built a platform that addresses patient information fragmentation by aggregating data from patient portals and providing direct access to lab testing. Health literacy is key to preventing chronic diseases, and AI is being used to scale the delivery of personalized health information. Identifying relevant biomarkers and early warning signs supports proactive health management that can alter long-term health outcomes.

Brent explains, "Beek Health is re-imagining healthcare by finally putting the individual at the center of their health journey. While we talk about patient-centric or customer-centric or shared decision-making...

Brent Dial, Founder and CEO of Beek Health, has built a platform that addresses patient information fragmentation by aggregating data from patient portals and providing direct access to lab testing. Health literacy is key to preventing chronic diseases, and AI is being used to scale the delivery of personalized health information. Identifying relevant biomarkers and early warning signs supports proactive health management that can alter long-term health outcomes.

Brent explains, "Beek Health is re-imagining healthcare by finally putting the individual at the center of their health journey. While we talk about patient-centric or customer-centric or shared decision-making...

Dr. Asher Eghbali, Co-Founder of Fuerte, has developed a platform to address the significant communication challenges between healthcare providers and pharmaceutical industry representatives. The goal is to streamline this relationship by replacing inefficient scheduling methods, and eliminate miscommunication and missed meetings to reduce frustrations and wasted time. The app is designed to combine professional networking with social media elements, including user profiles and notifications, to help build stronger, long-lasting professional relationships that benefit everyone involved.

Asher explains, "Within the life science companies and pharmaceutical reps, as we know, they're working very hard to commercialize medications and new...

Dr. Asher Eghbali, Co-Founder of Fuerte, has developed a platform to address the significant communication challenges between healthcare providers and pharmaceutical industry representatives. The goal is to streamline this relationship by replacing inefficient scheduling methods, and eliminate miscommunication and missed meetings to reduce frustrations and wasted time. The app is designed to combine professional networking with social media elements, including user profiles and notifications, to help build stronger, long-lasting professional relationships that benefit everyone involved.

Asher explains, "Within the life science companies and pharmaceutical reps, as we know, they're working very hard to commercialize medications and new...

Scott Pescatore, Executive VP of the Rare Diseases Business at Recordati, is focused on rare and ultra-orphan diseases with high unmet needs by acquiring promising compounds from other companies and advancing them through development and approval. An example is the company's drug Isturisa, acquired from Novartis, which is an FDA-approved effective treatment for patients with Cushing syndrome, a rare endocrine condition. Raising awareness of rare diseases among physicians, patients, and the general public is a priority for Recordati to improve diagnosis rates and clinical trial participation, and to encourage more research and funding in the rare disease space.

Scott Pescatore, Executive VP of the Rare Diseases Business at Recordati, is focused on rare and ultra-orphan diseases with high unmet needs by acquiring promising compounds from other companies and advancing them through development and approval. An example is the company's drug Isturisa, acquired from Novartis, which is an FDA-approved effective treatment for patients with Cushing syndrome, a rare endocrine condition. Raising awareness of rare diseases among physicians, patients, and the general public is a priority for Recordati to improve diagnosis rates and clinical trial participation, and to encourage more research and funding in the rare disease space.

Martin Burns, CEO of Bruin Biometrics, is focused on preventing pressure injuries, which are often not detected through visual and tactile assessments because damage starts invisibly under the skin. The Bruin scanner technology identifies pressure injuries by measuring sub-epidermal moisture, which can predict later tissue death, highlighting the condition that can be treated before it develops further. This handheld device is skin tone agnostic, addressing a significant health disparity and providing an objective number indicating the presence of excess fluid, allowing clinicians to act quickly.

Martin explains, "They are surprisingly common, and I emphasize surprisingly because pressure...

Martin Burns, CEO of Bruin Biometrics, is focused on preventing pressure injuries, which are often not detected through visual and tactile assessments because damage starts invisibly under the skin. The Bruin scanner technology identifies pressure injuries by measuring sub-epidermal moisture, which can predict later tissue death, highlighting the condition that can be treated before it develops further. This handheld device is skin tone agnostic, addressing a significant health disparity and providing an objective number indicating the presence of excess fluid, allowing clinicians to act quickly.

Martin explains, "They are surprisingly common, and I emphasize surprisingly because pressure...

Robert Jacks, President and CEO of Sparrow Pharmaceuticals, identifies that an elevated cortisol level is a newly recognized cause of treatment-resistant type 2 diabetes. A significant portion of patients with diabetes who do not respond to standard treatments, including GLP-1 agonists, have underlying high cortisol. Sparrow has developed a drug designed to lower cortisol levels inside cells, directly addressing the underlying driver of the disease, and to be used as a complement to existing treatments. This concept of targeting cortisol-driven resistance could be extended to other conditions, such as treatment-resistant hypertension.

Robert explains, "I feel as though Sparrow...

Robert Jacks, President and CEO of Sparrow Pharmaceuticals, identifies that an elevated cortisol level is a newly recognized cause of treatment-resistant type 2 diabetes. A significant portion of patients with diabetes who do not respond to standard treatments, including GLP-1 agonists, have underlying high cortisol. Sparrow has developed a drug designed to lower cortisol levels inside cells, directly addressing the underlying driver of the disease, and to be used as a complement to existing treatments. This concept of targeting cortisol-driven resistance could be extended to other conditions, such as treatment-resistant hypertension.

Robert explains, "I feel as though Sparrow...

Jesse Levey, CEO and Founder of Longevity Health, has a focus on extending the health span not just the lifespan of more people by providing access to tools and preventative health information. Lessons learned from expensive concierge medical services are being applied to a broader population, driving down health costs and democratizing longevity medicine. Using AI to build a scalable and personalized approach to wellness not just sick care, Longevity Health aims to make an AI doctor available around the globe.

 Jesse explains, "Our mission is to help a billion people live to a hundred in good h...

Jesse Levey, CEO and Founder of Longevity Health, has a focus on extending the health span not just the lifespan of more people by providing access to tools and preventative health information. Lessons learned from expensive concierge medical services are being applied to a broader population, driving down health costs and democratizing longevity medicine. Using AI to build a scalable and personalized approach to wellness not just sick care, Longevity Health aims to make an AI doctor available around the globe.

 Jesse explains, "Our mission is to help a billion people live to a hundred in good h...

Sean Cassidy, CEO and Co-Founder of Lucem Health, is applying AI to identify patients at high risk of undiagnosed conditions like cancer and diabetes.  The goal is to facilitate earlier diagnosis and treatment by flagging patients that need screening based on the AI plaform's ability to analyze EHR data and demographics of diverse patient populations to ensure broad scalability. This technology was designed to integrate into existing clinical workflows for established screening procedures rather than making direct treatment recommendations. 

Sean explains, "The origin of the company, the idea for the company, originated within Mayo Clinic in about 2020. Ma...

Sean Cassidy, CEO and Co-Founder of Lucem Health, is applying AI to identify patients at high risk of undiagnosed conditions like cancer and diabetes.  The goal is to facilitate earlier diagnosis and treatment by flagging patients that need screening based on the AI plaform's ability to analyze EHR data and demographics of diverse patient populations to ensure broad scalability. This technology was designed to integrate into existing clinical workflows for established screening procedures rather than making direct treatment recommendations. 

Sean explains, "The origin of the company, the idea for the company, originated within Mayo Clinic in about 2020. Ma...

Dr. Waqaas Al-Siddiq, CEO and Founder of Biotricity, has designed a direct-to-consumer service to shift healthcare from a reactive to a preventive model by simplifying and accelerating access to remote cardiac screening. Applying AI to sift through patient data allows the cardiologist to focus on clinically relevant information and to identify sporadic, intermittent heart issues that are often difficult to detect using traditional heart screening techniques.  Waqaas predicts an expansion of specialized solutions using AI and large datasets to support clinicians and patients in the drive to identify early signs of disease.

Waqaas explains, "The thing that w...

Dr. Waqaas Al-Siddiq, CEO and Founder of Biotricity, has designed a direct-to-consumer service to shift healthcare from a reactive to a preventive model by simplifying and accelerating access to remote cardiac screening. Applying AI to sift through patient data allows the cardiologist to focus on clinically relevant information and to identify sporadic, intermittent heart issues that are often difficult to detect using traditional heart screening techniques.  Waqaas predicts an expansion of specialized solutions using AI and large datasets to support clinicians and patients in the drive to identify early signs of disease.

Waqaas explains, "The thing that w...

Neil Klompas, President and CEO of Augurex, has a mission to improve the diagnosis of autoimmune diseases, with a primary focus on axial spondyloarthritis, a form of inflammatory back pain that is often misdiagnosed. The Augurex blood test SpineStat is designed to differentiate axSpA from mechanical back pain by identifying a specific biomarker present in axSpA. Currently, there is an average nine-year delay from the onset of symptoms to an accurate diagnosis of axSpA, causing irreversible spinal damage and years of using drugs and therapy with no benefit.

Neil explains, "I think we're all familiar with back...

Neil Klompas, President and CEO of Augurex, has a mission to improve the diagnosis of autoimmune diseases, with a primary focus on axial spondyloarthritis, a form of inflammatory back pain that is often misdiagnosed. The Augurex blood test SpineStat is designed to differentiate axSpA from mechanical back pain by identifying a specific biomarker present in axSpA. Currently, there is an average nine-year delay from the onset of symptoms to an accurate diagnosis of axSpA, causing irreversible spinal damage and years of using drugs and therapy with no benefit.

Neil explains, "I think we're all familiar with back...

Dr. Petri Bono, Chief Medical Officer at Faron Pharmaceuticals, describes the development of bexmarilimad, a novel first-in-class immunotherapy that, unlike existing checkpoint inhibitors targeting T cells, targets the Clever 1 receptor on macrophages. This treatment is designed to reprogram the tumor microenvironment by switching marcophages from suppressive to active, enabling the patient's immune system to recognize and attack cancer cells. The primary disease target is higher-risk Myelodysplastic syndromes because the cancer cells in virtually all MDS patients express the Clever 1 target.

Petri explains, "We are developing a completely new type of treatment. Currently, cancer patients are treated with...

Dr. Petri Bono, Chief Medical Officer at Faron Pharmaceuticals, describes the development of bexmarilimad, a novel first-in-class immunotherapy that, unlike existing checkpoint inhibitors targeting T cells, targets the Clever 1 receptor on macrophages. This treatment is designed to reprogram the tumor microenvironment by switching marcophages from suppressive to active, enabling the patient's immune system to recognize and attack cancer cells. The primary disease target is higher-risk Myelodysplastic syndromes because the cancer cells in virtually all MDS patients express the Clever 1 target.

Petri explains, "We are developing a completely new type of treatment. Currently, cancer patients are treated with...

Todd Doze, CEO of Janus Health, specializes in bringing AI to hospitals to connect the hospital revenue cycle management with the overall patient experience. Automating some manual RCM tasks, such as prior authorizations and referrals,  has led to significant reductions in claim denials, faster processing times, fewer errors, and better compliance with recent legislation. Challenges remain to ensure the AI model's accuracy and to demonstrate clear ROI and a direct impact on the hospital's revenue.

Todd explains, "Today at Janus, we focus on helping providers improve their operational and financial efficiency. We work with about 250 acute care h...

Todd Doze, CEO of Janus Health, specializes in bringing AI to hospitals to connect the hospital revenue cycle management with the overall patient experience. Automating some manual RCM tasks, such as prior authorizations and referrals,  has led to significant reductions in claim denials, faster processing times, fewer errors, and better compliance with recent legislation. Challenges remain to ensure the AI model's accuracy and to demonstrate clear ROI and a direct impact on the hospital's revenue.

Todd explains, "Today at Janus, we focus on helping providers improve their operational and financial efficiency. We work with about 250 acute care h...

Susan Grant, Chief Clinical Officer at symplr, reviews findings from their annual Compass Survey, which revealed the significant challenges hospitals face, driven by financial pressures, clinician burnout, and operational inefficiencies.  Fragmented technology systems create significant administrative burdens, and there is growing recognition that unifying healthcare operations and strategically implementing AI are crucial to streamlining workflows. Clinicians' involvement in the design and implementation of new processes and procedures is essential to ensure that patients' real-world needs are properly addressed.

Susan explains, "The annual Compass Survey, is actually our fourth survey that we've done here at symplr, and the g...

Susan Grant, Chief Clinical Officer at symplr, reviews findings from their annual Compass Survey, which revealed the significant challenges hospitals face, driven by financial pressures, clinician burnout, and operational inefficiencies.  Fragmented technology systems create significant administrative burdens, and there is growing recognition that unifying healthcare operations and strategically implementing AI are crucial to streamlining workflows. Clinicians' involvement in the design and implementation of new processes and procedures is essential to ensure that patients' real-world needs are properly addressed.

Susan explains, "The annual Compass Survey, is actually our fourth survey that we've done here at symplr, and the g...

Fawad Butt, Co-Founder and CEO of Penguin AI,  is addressing the workflow challenges faced by healthcare payers and providers, particularly in prior authorizations and claims adjudications. These processes are inefficient and often yield inconsistent results because human reviewers interpret rules differently, and patients are denied care due to minor administrative errors.   Penguin AI is bringing consistency and speed to adjudication, breaking down data silos and handling non-clinical administrative work, enabling agents to address patient-specific problems and ensure accuracy and safety.

Fawad explains, "When you look at the healthcare ecosystem, there are obviously the pharma side, the payer sid...

Fawad Butt, Co-Founder and CEO of Penguin AI,  is addressing the workflow challenges faced by healthcare payers and providers, particularly in prior authorizations and claims adjudications. These processes are inefficient and often yield inconsistent results because human reviewers interpret rules differently, and patients are denied care due to minor administrative errors.   Penguin AI is bringing consistency and speed to adjudication, breaking down data silos and handling non-clinical administrative work, enabling agents to address patient-specific problems and ensure accuracy and safety.

Fawad explains, "When you look at the healthcare ecosystem, there are obviously the pharma side, the payer sid...

Alexander Tsiaras, CEO and Founder of StoryMD, is addressing the critical problem of the fragmented health information landscape. The StoryMD platform unifies a patient's health history, including clinical records, wearable data, and personal diary entries, along with relevant data from a vast validated medical library of text and strong visualizations.  This provides a coherent narrative about the patient that informs the patient, their healthcare providers, and caregivers, enabling more informed decisions and better outcomes.

Alexander explains, "So one of the huge problems that we have in healthcare is that when people go through a health journey, they h...

Alexander Tsiaras, CEO and Founder of StoryMD, is addressing the critical problem of the fragmented health information landscape. The StoryMD platform unifies a patient's health history, including clinical records, wearable data, and personal diary entries, along with relevant data from a vast validated medical library of text and strong visualizations.  This provides a coherent narrative about the patient that informs the patient, their healthcare providers, and caregivers, enabling more informed decisions and better outcomes.

Alexander explains, "So one of the huge problems that we have in healthcare is that when people go through a health journey, they h...

Seth Cohen, President of Cedar, is addressing the affordability of health care by shifting the emphasis from billing functionality to patient financial navigation by using technology to connect patients to underutilized financial resources. The Cedar Cover platform is designed to identify and enroll eligible uninsured or underinsured patients into Medicaid, ACA, available pharmaceutical copay subsidies, and untapped Health Savings Accounts, which can be used retrospectively to cover previous medical and ongoing bills, benefiting the patient and providers. An AI agent handles patient service calls to help patients navigate the challenges of connecting to these resources and identifying new coverage...

Seth Cohen, President of Cedar, is addressing the affordability of health care by shifting the emphasis from billing functionality to patient financial navigation by using technology to connect patients to underutilized financial resources. The Cedar Cover platform is designed to identify and enroll eligible uninsured or underinsured patients into Medicaid, ACA, available pharmaceutical copay subsidies, and untapped Health Savings Accounts, which can be used retrospectively to cover previous medical and ongoing bills, benefiting the patient and providers. An AI agent handles patient service calls to help patients navigate the challenges of connecting to these resources and identifying new coverage...

Jim Foote, Co-Founder and CEO of First Ascent Biomedical, is changing the standard of care for cancer treatment from 'try and hope' to 'test and treat'. The First Ascent platform combines functional drug testing of fresh biopsies, genomic sequencing, and an AI engine to assess a large panel of drugs and identify the most likely to be effective. Clinical data show a high correlation between how cancer cells respond in the lab test and how patients respond to the same drug, and is seen as a treatment guide for refractory cancer patients to identify novel drug combinations.

...

Jim Foote, Co-Founder and CEO of First Ascent Biomedical, is changing the standard of care for cancer treatment from 'try and hope' to 'test and treat'. The First Ascent platform combines functional drug testing of fresh biopsies, genomic sequencing, and an AI engine to assess a large panel of drugs and identify the most likely to be effective. Clinical data show a high correlation between how cancer cells respond in the lab test and how patients respond to the same drug, and is seen as a treatment guide for refractory cancer patients to identify novel drug combinations.

...

Deb Nevins, Director of Product Strategy at POCN, emphasizes the expanding role and importance of Nurse Practitioners and Physician Associates in the American healthcare system.  These professionals have evolved from being an extension of the physician to becoming autonomous clinicians who handle a wide range of patient care, including diagnosing, prescribing, and creating treatment plans for a significant portion of the patient population. In many cases, NPs and PAs are filling care gaps in rural and underserved areas and applying a more holistic approach to healthcare in an increasingly virtual healthcare environment.

Deb explains, "POCN is an o...

Deb Nevins, Director of Product Strategy at POCN, emphasizes the expanding role and importance of Nurse Practitioners and Physician Associates in the American healthcare system.  These professionals have evolved from being an extension of the physician to becoming autonomous clinicians who handle a wide range of patient care, including diagnosing, prescribing, and creating treatment plans for a significant portion of the patient population. In many cases, NPs and PAs are filling care gaps in rural and underserved areas and applying a more holistic approach to healthcare in an increasingly virtual healthcare environment.

Deb explains, "POCN is an o...

Jill Eubank, Division President of Professional Talent Solutions at Randstad USA, shares key findings from the Randstad Work Monitor Pulse Survey on the current landscape in the medical and healthcare industry. Noted is the significant shift from prioritizing remote work to job security, alignment with leadership values, and how AI is being used to improve job efficiency.  In an environment facing a scarcity of qualified employees, retention drivers include pay increases that keep pace with inflation, flexible scheduling, and strong manager support.

Jill explains, "We're the largest staffing and workforce solution provider in the country and really i...

Jill Eubank, Division President of Professional Talent Solutions at Randstad USA, shares key findings from the Randstad Work Monitor Pulse Survey on the current landscape in the medical and healthcare industry. Noted is the significant shift from prioritizing remote work to job security, alignment with leadership values, and how AI is being used to improve job efficiency.  In an environment facing a scarcity of qualified employees, retention drivers include pay increases that keep pace with inflation, flexible scheduling, and strong manager support.

Jill explains, "We're the largest staffing and workforce solution provider in the country and really i...

David Bates, CEO and Co-Founder of Linus Health, highlights the need to monitor brain health to identify the earliest signs of cognitive decline. The Linus Health AI-powered platform enables primary care providers to quickly screen for, diagnose, and help manage cognitive issues for an expanding population. Striving to overcome stigma and bias, this approach to early detection is crucial because many underlying causes of cognitive decline are treatable or reversible.

David explains, "In brain health, especially, I'll talk first about cognitive health. There are up to 15 million Americans right now who have mild cognitive impairment, which is...

David Bates, CEO and Co-Founder of Linus Health, highlights the need to monitor brain health to identify the earliest signs of cognitive decline. The Linus Health AI-powered platform enables primary care providers to quickly screen for, diagnose, and help manage cognitive issues for an expanding population. Striving to overcome stigma and bias, this approach to early detection is crucial because many underlying causes of cognitive decline are treatable or reversible.

David explains, "In brain health, especially, I'll talk first about cognitive health. There are up to 15 million Americans right now who have mild cognitive impairment, which is...

Mike Hoxter, CTO of Lightbeam Health Solutions, is focused on applying AI to population health management by using predictive models to enhance risk stratification for organizations with value-based care contracts. He emphasizes the importance of integrating social determinants of health along with clinical data to create more accurate predictive scores for patient outcomes, such as reducing hospital readmissions. AI enables a model to incorporate diverse data to derive more fine-tuned, actionable predictions.

Mike explains, "We're really all for optimization in value-based care plans and care management. That's really our bread and butter, which is a pretty wide n...

Mike Hoxter, CTO of Lightbeam Health Solutions, is focused on applying AI to population health management by using predictive models to enhance risk stratification for organizations with value-based care contracts. He emphasizes the importance of integrating social determinants of health along with clinical data to create more accurate predictive scores for patient outcomes, such as reducing hospital readmissions. AI enables a model to incorporate diverse data to derive more fine-tuned, actionable predictions.

Mike explains, "We're really all for optimization in value-based care plans and care management. That's really our bread and butter, which is a pretty wide n...

Adam David, CEO of Doctors House Calls, has identified a gap in healthcare for homebound, high-acuity patients who lack a primary care physician, which often leads to frequent hospital admissions. This service operates primarily for Medicare patients by deploying physicians, PAs, and nurse practitioners to provide comprehensive care in patients' homes. Technology, such as connected devices, AI, and portable diagnostic equipment, enables efficient and effective visits to provide proactive care, extending the range of services available to this population.

 Adam explains, "I put together Doctors House Calls, not to compete in the business of treating patients in a...

Adam David, CEO of Doctors House Calls, has identified a gap in healthcare for homebound, high-acuity patients who lack a primary care physician, which often leads to frequent hospital admissions. This service operates primarily for Medicare patients by deploying physicians, PAs, and nurse practitioners to provide comprehensive care in patients' homes. Technology, such as connected devices, AI, and portable diagnostic equipment, enables efficient and effective visits to provide proactive care, extending the range of services available to this population.

 Adam explains, "I put together Doctors House Calls, not to compete in the business of treating patients in a...

Linda Schatz, Director of AKASA, explains the role of Clinical Documentation Integrity (CDI) specialists in ensuring accurate coding and bridging the gap between clinical documentation and specific, accurate codes to ensure proper reimbursement. The complexity of medical coding often leads to errors, which can be nearly eliminated by using AI to review 100% of patient encounters to identify inconsistencies and help CDI and coding professionals process more accurate claims quickly. Accurate documentation is important for hospital revenue, patient care quality, and perception of the hospital's performance.

Linda explains, "Well, the old adage, if it isn't documented, it wasn't...

Linda Schatz, Director of AKASA, explains the role of Clinical Documentation Integrity (CDI) specialists in ensuring accurate coding and bridging the gap between clinical documentation and specific, accurate codes to ensure proper reimbursement. The complexity of medical coding often leads to errors, which can be nearly eliminated by using AI to review 100% of patient encounters to identify inconsistencies and help CDI and coding professionals process more accurate claims quickly. Accurate documentation is important for hospital revenue, patient care quality, and perception of the hospital's performance.

Linda explains, "Well, the old adage, if it isn't documented, it wasn't...

Tina Liedtky, President of Transplant Diagnostics at Thermo Fisher Scientific, identifies the significant challenges in the US organ transplant system that must be addressed to meet the demand for organs.  Patient access to transplant care is hindered by geography, the need to match donors and recipients, and the threat of organ rejection. Living donations, particularly of kidneys and livers, are a solution to address the organ shortage, as organs from living donors often lead to better outcomes and can be scheduled to avoid damage caused by organ transportation.

Tina explains, "So first of all, I would say t...

Tina Liedtky, President of Transplant Diagnostics at Thermo Fisher Scientific, identifies the significant challenges in the US organ transplant system that must be addressed to meet the demand for organs.  Patient access to transplant care is hindered by geography, the need to match donors and recipients, and the threat of organ rejection. Living donations, particularly of kidneys and livers, are a solution to address the organ shortage, as organs from living donors often lead to better outcomes and can be scheduled to avoid damage caused by organ transportation.

Tina explains, "So first of all, I would say t...

Dr. Sev MacLaughlin, the CEO of DeLorean AI, has developed an AI platform to identify at-risk patients, including those with renal disease, cardiovascular disease, and mental health conditions. Serving smaller and mid-sized provider clinics, this approach supports the shift to value-based care by predicting adverse events, recommending preventive measures, and reducing hospitalizations and healthcare costs. By analyzing entire populations instead of samples, the platform avoids biases and overlooked subgroups inherent in traditional analytical methods.

Sev explains, "So I think there's an opportunity to not only give better care at the point of care, but also aid in...

Dr. Sev MacLaughlin, the CEO of DeLorean AI, has developed an AI platform to identify at-risk patients, including those with renal disease, cardiovascular disease, and mental health conditions. Serving smaller and mid-sized provider clinics, this approach supports the shift to value-based care by predicting adverse events, recommending preventive measures, and reducing hospitalizations and healthcare costs. By analyzing entire populations instead of samples, the platform avoids biases and overlooked subgroups inherent in traditional analytical methods.

Sev explains, "So I think there's an opportunity to not only give better care at the point of care, but also aid in...

Antoine Pivron, Vice President of Health Solutions in the B2B division at Withings, highlights the clinical-grade connected devices that are changing the remote patient monitoring market. The equipment and AI-enhanced tools are designed to focus on personalized patient engagement and retention, ultimately leading to improved health outcomes. The data made available identifies trends over time, allowing for intervention when necessary, and is presented in a form that emphasizes prevention rather than reaction.

Antoine explains, "We are very well known for our connected devices, especially the weight scales. So we were the first company back in 2009 to...

Antoine Pivron, Vice President of Health Solutions in the B2B division at Withings, highlights the clinical-grade connected devices that are changing the remote patient monitoring market. The equipment and AI-enhanced tools are designed to focus on personalized patient engagement and retention, ultimately leading to improved health outcomes. The data made available identifies trends over time, allowing for intervention when necessary, and is presented in a form that emphasizes prevention rather than reaction.

Antoine explains, "We are very well known for our connected devices, especially the weight scales. So we were the first company back in 2009 to...

Dr. Jay Lalezari, CEO of CytoDyn, is focused on solid tumor immunology, particularly in triple-negative breast cancer, where their lead drug, leronlimab, is showing significant long-term survival benefits.  This monoclonal antibody targets the CCR5 receptor, converting cold tumors into hot tumors and making them more susceptible to immunotherapy checkpoint inhibitors. Work with leronlimab for 20 years has demonstrated the potential for use in colorectal cancer as well as TNBC, and to vastly expand the patient population that could benefit from immunotherapy.

Jay explains, "When I became CEO back in November of 2023, my first order of business was to f...

Dr. Jay Lalezari, CEO of CytoDyn, is focused on solid tumor immunology, particularly in triple-negative breast cancer, where their lead drug, leronlimab, is showing significant long-term survival benefits.  This monoclonal antibody targets the CCR5 receptor, converting cold tumors into hot tumors and making them more susceptible to immunotherapy checkpoint inhibitors. Work with leronlimab for 20 years has demonstrated the potential for use in colorectal cancer as well as TNBC, and to vastly expand the patient population that could benefit from immunotherapy.

Jay explains, "When I became CEO back in November of 2023, my first order of business was to f...

Andrew Rosen, Chief Executive Officer of the National Ataxia Foundation, has a dual mission of accelerating research for treatments and cures for Ataxia while supporting the patients affected by this rare disease. Ataxia describes both a group of hereditary genetic diseases and symptoms of lack of coordination seen in other conditions.  While genetic tests exist for hereditary Ataxia, a significant challenge in drug development has been the lack of a reliable biomarker. To encourage drug development, NAF has funded translational research and the world's most extensive study for SCAs, Spinocerebellar Ataxias, providing new data on the progression of the d...

Andrew Rosen, Chief Executive Officer of the National Ataxia Foundation, has a dual mission of accelerating research for treatments and cures for Ataxia while supporting the patients affected by this rare disease. Ataxia describes both a group of hereditary genetic diseases and symptoms of lack of coordination seen in other conditions.  While genetic tests exist for hereditary Ataxia, a significant challenge in drug development has been the lack of a reliable biomarker. To encourage drug development, NAF has funded translational research and the world's most extensive study for SCAs, Spinocerebellar Ataxias, providing new data on the progression of the d...

Anne Meneghetti, Executive  Director of epocrates, is focused on medication management and providing tools for clinicians to better handle challenges from the increasing population of patients who take multiple drugs and are treating a wide variety of conditions. The epocrates app provides access to drug information, pill identification, checks for interactions, and calculates dosing, reducing medication errors and patient confusion. Polypharmacy patients are further at risk when they are taking over-the-counter drugs and supplements, requiring regular medication reconcilation to avoid serious drug interactions.

Anne explains, "So epocrates has been around since the late 1990s, and it's the n...

Anne Meneghetti, Executive  Director of epocrates, is focused on medication management and providing tools for clinicians to better handle challenges from the increasing population of patients who take multiple drugs and are treating a wide variety of conditions. The epocrates app provides access to drug information, pill identification, checks for interactions, and calculates dosing, reducing medication errors and patient confusion. Polypharmacy patients are further at risk when they are taking over-the-counter drugs and supplements, requiring regular medication reconcilation to avoid serious drug interactions.

Anne explains, "So epocrates has been around since the late 1990s, and it's the n...

Dr. Adam Kilian, Director of the Rheumatology Fellowship Training Program at the St. Louis University School of Medicine, focuses on IgG4-related disease, a rare multi-organ disease that has only recently been recognized due to significant diagnostic challenges. The MITIGATE trial is a landmark study that demonstrated that the first FDA-approved treatment, UPLIZNA from Amgen, provides an effective, targeted, steroid-free therapy. The approval of this drug is driving awareness in the medical community about IgG4-RD and whether the disease should be considered after inconclusive results for other suspected conditions.

Adam explains, "IgG4-related disease is a...

Dr. Adam Kilian, Director of the Rheumatology Fellowship Training Program at the St. Louis University School of Medicine, focuses on IgG4-related disease, a rare multi-organ disease that has only recently been recognized due to significant diagnostic challenges. The MITIGATE trial is a landmark study that demonstrated that the first FDA-approved treatment, UPLIZNA from Amgen, provides an effective, targeted, steroid-free therapy. The approval of this drug is driving awareness in the medical community about IgG4-RD and whether the disease should be considered after inconclusive results for other suspected conditions.

Adam explains, "IgG4-related disease is a...

Dr. Thomas Wisniewski, Director of NYU Langone's Alzheimer's Disease Research Center, shares insights from a recent study that projects new dementia cases in the US will double by 2060. New diagnostic tools have made it easier to identify early signs of Alzheimer's, and disease-modifying therapies are being approved, which can be effective if patients are treated in the earliest stages of the disease. AI is seen as a tool to help identify at-risk patients and routinely screen patients to manage the growing need for access to dementia care.

 Thomas explains, "This was a study that was led by t...

Dr. Thomas Wisniewski, Director of NYU Langone's Alzheimer's Disease Research Center, shares insights from a recent study that projects new dementia cases in the US will double by 2060. New diagnostic tools have made it easier to identify early signs of Alzheimer's, and disease-modifying therapies are being approved, which can be effective if patients are treated in the earliest stages of the disease. AI is seen as a tool to help identify at-risk patients and routinely screen patients to manage the growing need for access to dementia care.

 Thomas explains, "This was a study that was led by t...

Pedro Sanchez de Lozada, CEO of Canid, highlights the significant financial risks that pediatricians face in managing their vaccine inventory.  There are administrative burdens associated with ordering, patient demand, tracking, reporting, and filing for insurance reimbursement. The Canid platform was designed to be a vaccine-as-a-service model, removing risk and administrative work from pediatric practices, allowing small and independent practices to achieve economies of scale, and freeing up more time to spend with patients and their parents.

 Pedro explains, "When managing a vaccine program, the expectation is that the pediatrician will buy and maintain the stock in their of...

Pedro Sanchez de Lozada, CEO of Canid, highlights the significant financial risks that pediatricians face in managing their vaccine inventory.  There are administrative burdens associated with ordering, patient demand, tracking, reporting, and filing for insurance reimbursement. The Canid platform was designed to be a vaccine-as-a-service model, removing risk and administrative work from pediatric practices, allowing small and independent practices to achieve economies of scale, and freeing up more time to spend with patients and their parents.

 Pedro explains, "When managing a vaccine program, the expectation is that the pediatrician will buy and maintain the stock in their of...

Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations.

Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we...

Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations.

Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we...

Dr. Stacy Lindborg, President and CEO of IMUNON, has developed a DNA-based immunotherapy candidate for the treatment of ovarian cancer. This therapy works by administering the drug, which utilizes IL-12, a powerful anti-cancer cytokine, directly into the cavity where the cancer resides, thereby affecting the tumor microenvironment. Trials are showing that the drug can produce significant life extension when used in combination with standard chemotherapy.

Stacy explains, "There are about 300,000 women who are newly diagnosed with advanced ovarian cancer every year, about 20,000 in the US, and the frontline standard of care hasn't seen a change in the t...

Dr. Stacy Lindborg, President and CEO of IMUNON, has developed a DNA-based immunotherapy candidate for the treatment of ovarian cancer. This therapy works by administering the drug, which utilizes IL-12, a powerful anti-cancer cytokine, directly into the cavity where the cancer resides, thereby affecting the tumor microenvironment. Trials are showing that the drug can produce significant life extension when used in combination with standard chemotherapy.

Stacy explains, "There are about 300,000 women who are newly diagnosed with advanced ovarian cancer every year, about 20,000 in the US, and the frontline standard of care hasn't seen a change in the t...

Donovan Campbell, CEO of Medbridge, empowers clinicians through a platform that is focused on movement-based medicine and a holistic approach to patient care. MedBridge has developed AI tools to perform triage, act as a care coordinator, and serve as a patient-facing coach, offloading administrative tasks and providing better support to patients. These tools are designed to support clinicians by flagging potential issues and increasing patient engagement by delivering immediate digital access to care. 

Donovan explains, "We serve primarily physical therapists. And those physical therapists can work either in what's called a private practice outpatient setting or in a...

Donovan Campbell, CEO of Medbridge, empowers clinicians through a platform that is focused on movement-based medicine and a holistic approach to patient care. MedBridge has developed AI tools to perform triage, act as a care coordinator, and serve as a patient-facing coach, offloading administrative tasks and providing better support to patients. These tools are designed to support clinicians by flagging potential issues and increasing patient engagement by delivering immediate digital access to care. 

Donovan explains, "We serve primarily physical therapists. And those physical therapists can work either in what's called a private practice outpatient setting or in a...

Dr. Matt Goldstein, CEO of jscreen, focuses on the importance and power of preventive genetic testing for reproductive carrier screening and hereditary cancer screening. All genetic tests include analysis to inform specific medical management plans and provide genetic counselors to explore options. Of particular interest is testing for the gene mutations that cause Tay-Sachs disease and helping families take proactive steps to effectively eliminate the disease in future generations.

Matt explains, "So, jscreen is a nonprofit that focuses on providing access to education and high-touch support to individuals, families, and to clinicians in the area of preventive...

Dr. Matt Goldstein, CEO of jscreen, focuses on the importance and power of preventive genetic testing for reproductive carrier screening and hereditary cancer screening. All genetic tests include analysis to inform specific medical management plans and provide genetic counselors to explore options. Of particular interest is testing for the gene mutations that cause Tay-Sachs disease and helping families take proactive steps to effectively eliminate the disease in future generations.

Matt explains, "So, jscreen is a nonprofit that focuses on providing access to education and high-touch support to individuals, families, and to clinicians in the area of preventive...

Dr. Yuri Maricich, Chief Medical Officer at CAMP4 Therapeutics, describes regulatory RNA, a new area of biology that recognizes the role of Reg RNA in the production of proteins from specific genes. This technology is well-suited for haploinsufficient diseases such as SYNGAP1-related disorders, in which there is a lack of healthy protein and both parents carry a copy of the mutated gene. The goal is to create disease-modifying treatments that correct the underlying genetic cause rather than treating the symptoms.

Yuri explains, "What was really unique about CAMP4's scientific approach is that we're focused on a...

Dr. Yuri Maricich, Chief Medical Officer at CAMP4 Therapeutics, describes regulatory RNA, a new area of biology that recognizes the role of Reg RNA in the production of proteins from specific genes. This technology is well-suited for haploinsufficient diseases such as SYNGAP1-related disorders, in which there is a lack of healthy protein and both parents carry a copy of the mutated gene. The goal is to create disease-modifying treatments that correct the underlying genetic cause rather than treating the symptoms.

Yuri explains, "What was really unique about CAMP4's scientific approach is that we're focused on a...

Phil L'Huillier, CEO of Scancell,  has developed an off-the-shelf DNA immunotherapy designed to generate a potent and durable immune response against advanced melanoma in patients who are unresponsive to current therapies. Their lead candidate showed significant benefit when added to standard of care checkpoint inhibitors, improving duration of response without adding side effects or toxicity. Patient selection in future trials will use a blood test to identify the immune types that can be expected to respond best to the therapy.

Phil explains, "Perhaps first and foremost, Scancell is a clinical-stage company developing novel active immunotherapies for patients. A...

Phil L'Huillier, CEO of Scancell,  has developed an off-the-shelf DNA immunotherapy designed to generate a potent and durable immune response against advanced melanoma in patients who are unresponsive to current therapies. Their lead candidate showed significant benefit when added to standard of care checkpoint inhibitors, improving duration of response without adding side effects or toxicity. Patient selection in future trials will use a blood test to identify the immune types that can be expected to respond best to the therapy.

Phil explains, "Perhaps first and foremost, Scancell is a clinical-stage company developing novel active immunotherapies for patients. A...

Dr. Costas Karatzas, CEO, Director, and Co-Founder of Acesis BioMed, is focused on developing a novel treatment for low testosterone in men, an oral peptide that stimulates the body to restore its own natural testosterone production. The therapy's mechanism differs from current testosterone replacement therapies and avoids the side effect of infertility seen in younger men using traditional TRT, which shuts down natural hormone and sperm production. This low T condition is not just a function of aging but is increasingly affecting younger men due to lifestyle, environmental factors, and co-morbidities like diabetes and obesity.

Costas explains, "...

Dr. Costas Karatzas, CEO, Director, and Co-Founder of Acesis BioMed, is focused on developing a novel treatment for low testosterone in men, an oral peptide that stimulates the body to restore its own natural testosterone production. The therapy's mechanism differs from current testosterone replacement therapies and avoids the side effect of infertility seen in younger men using traditional TRT, which shuts down natural hormone and sperm production. This low T condition is not just a function of aging but is increasingly affecting younger men due to lifestyle, environmental factors, and co-morbidities like diabetes and obesity.

Costas explains, "...

Dr. Adam Rogers, CEO of NervGen Pharma, highlights the significant unmet medical need for treating spinal cord injuries (SCI), as there are currently no approved pharmacological treatments to promote repair.  The science behind this neurotrauma company's drug is designed to interfere with the inhibitory molecules that prevent neurons from regenerating after injury, allowing the nervous system to repair itself. Recent trials have shown success in patients with chronic SCI, indicating that it is possible to promote recovery long after initial damage occurs..

Adam explains, "Our mission at NervGen is to improve the lives of individuals with spinal c...

Dr. Adam Rogers, CEO of NervGen Pharma, highlights the significant unmet medical need for treating spinal cord injuries (SCI), as there are currently no approved pharmacological treatments to promote repair.  The science behind this neurotrauma company's drug is designed to interfere with the inhibitory molecules that prevent neurons from regenerating after injury, allowing the nervous system to repair itself. Recent trials have shown success in patients with chronic SCI, indicating that it is possible to promote recovery long after initial damage occurs..

Adam explains, "Our mission at NervGen is to improve the lives of individuals with spinal c...

Dr. Sanjay Kakkar, CEO of Tensive, has developed an innovative bioresorbable polymeric scaffold for breast regeneration following a lumpectomy.  The scaffold was designed to address a significant unmet need for breast cancer patients who have limited options for reconstruction. A key feature of this technology is that it facilitates a natural wound-healing response, allowing the body's own vascular, connective, and fat tissues to regrow as the scaffold gradually dissolves.

Sanjay explains, "What we've been developing at Tensive is at a late clinical stage of these advanced biomaterials, and we've spent the last decade or so pioneering this b...

Dr. Sanjay Kakkar, CEO of Tensive, has developed an innovative bioresorbable polymeric scaffold for breast regeneration following a lumpectomy.  The scaffold was designed to address a significant unmet need for breast cancer patients who have limited options for reconstruction. A key feature of this technology is that it facilitates a natural wound-healing response, allowing the body's own vascular, connective, and fat tissues to regrow as the scaffold gradually dissolves.

Sanjay explains, "What we've been developing at Tensive is at a late clinical stage of these advanced biomaterials, and we've spent the last decade or so pioneering this b...

Dr. Saria Saccocio, Chief Medical Officer at Essence Healthcare, is using AI to enhance care and services for patients who are enrolled in Medicare Advantage programs. One application is to analyze data related to health equity, care authorization, and to address biases. Their AI agent is being used to interact with patients, offering them the option to access a human. Integration with wearables, such as the Oura Ring, focuses on identifying clinically useful information to prevent physicians from being overwhelmed by data.

Saria explains, "Medicare Advantage plans are absolutely that. It's an advantage because of the additional...

Dr. Saria Saccocio, Chief Medical Officer at Essence Healthcare, is using AI to enhance care and services for patients who are enrolled in Medicare Advantage programs. One application is to analyze data related to health equity, care authorization, and to address biases. Their AI agent is being used to interact with patients, offering them the option to access a human. Integration with wearables, such as the Oura Ring, focuses on identifying clinically useful information to prevent physicians from being overwhelmed by data.

Saria explains, "Medicare Advantage plans are absolutely that. It's an advantage because of the additional...

Kerry Mello-Parker, Director of Rare Diseases and REMS programs at Shields Health Solutions, addresses the complexities and challenges faced by patients with rare diseases including diagnostic delays and limited access to medication. Using an integrated specialty pharmacy model, Shields works with pharmacists to have direct access to the EHR, enabling better patient monitoring, shorter time to initiate medication, tracking outcomes, and providing patients with a direct line of communication to their care team. Pharmacists treating rare diseases are also supported with specialized information on medication administration, side effects and complex billing. 

Kerry explains, "Shields Health Solutions is a...

Kerry Mello-Parker, Director of Rare Diseases and REMS programs at Shields Health Solutions, addresses the complexities and challenges faced by patients with rare diseases including diagnostic delays and limited access to medication. Using an integrated specialty pharmacy model, Shields works with pharmacists to have direct access to the EHR, enabling better patient monitoring, shorter time to initiate medication, tracking outcomes, and providing patients with a direct line of communication to their care team. Pharmacists treating rare diseases are also supported with specialized information on medication administration, side effects and complex billing. 

Kerry explains, "Shields Health Solutions is a...

Ram Sahasranam, President and Co-Founder of Fold Health, has created a platform that integrates with the EHR to create an AI-driven interface that streamlines workflows, improves communication across the care team, and helps better manage patient care. Traditional EHR systems, while effective for documentation, were not built for proactive care and data sharing. With a focus on the patient and providers, Fold Health is integrating data sources and automating redundant administrative tasks helping to reduce clinician burnout and improve patient communication for scheduling and reminders.

Ram explains, "The way to look at it is that empowering providers...

Ram Sahasranam, President and Co-Founder of Fold Health, has created a platform that integrates with the EHR to create an AI-driven interface that streamlines workflows, improves communication across the care team, and helps better manage patient care. Traditional EHR systems, while effective for documentation, were not built for proactive care and data sharing. With a focus on the patient and providers, Fold Health is integrating data sources and automating redundant administrative tasks helping to reduce clinician burnout and improve patient communication for scheduling and reminders.

Ram explains, "The way to look at it is that empowering providers...

Ralph Keiser, CEO of ArcheHealth, highlights the severe financial pressures that hospitals are confronting as a result of rising costs and declining reimbursements. Reductions in reimbursements are threatening hospitals that serve underinsured populations. Costs are increasing due to tariffs on medical device components and the general price inflation on medical supplies and drugs.  ArcheHealth is focused on helping hospitals improve operational efficiency to lower the expense of delivering care.

Ralph explains, "The tariff index is going to come mostly around medical devices and device components. So plastics, metals, packaging, things that the device manufacturers use to deliver t...

Ralph Keiser, CEO of ArcheHealth, highlights the severe financial pressures that hospitals are confronting as a result of rising costs and declining reimbursements. Reductions in reimbursements are threatening hospitals that serve underinsured populations. Costs are increasing due to tariffs on medical device components and the general price inflation on medical supplies and drugs.  ArcheHealth is focused on helping hospitals improve operational efficiency to lower the expense of delivering care.

Ralph explains, "The tariff index is going to come mostly around medical devices and device components. So plastics, metals, packaging, things that the device manufacturers use to deliver t...

Dr. Marc Salzberg, President, CEO, and Chief Medical Officer at Airway Therapeutics, is developing a drug AT-100 to prevent bronchopulmonary dysplasia (BPD) in preterm infants, a severe condition with no existing treatment. These infants are at high risk for BPD because of a low level of a protective protein that reduces inflammation and clears infections from their underdeveloped lungs. The drug's mechanism of action suggests it has potential for treating other inflammatory conditions such as asthma, COPD, and severe pneumonia.

Marc explains, "We're focusing on developing drugs or interventions for severe respiratory conditions for prevention or treatment...

Dr. Marc Salzberg, President, CEO, and Chief Medical Officer at Airway Therapeutics, is developing a drug AT-100 to prevent bronchopulmonary dysplasia (BPD) in preterm infants, a severe condition with no existing treatment. These infants are at high risk for BPD because of a low level of a protective protein that reduces inflammation and clears infections from their underdeveloped lungs. The drug's mechanism of action suggests it has potential for treating other inflammatory conditions such as asthma, COPD, and severe pneumonia.

Marc explains, "We're focusing on developing drugs or interventions for severe respiratory conditions for prevention or treatment...

 Wade Demmer, R&D Vice President at Medtronic, has developed a leadless pacemaker that is implanted on the heart through a minimally invasive procedure utilizing a catheter, potentially creating fewer complications and greater access for patients who could benefit from a pacemaker. This new design is a significantly smaller, safer, and longer-lasting device than traditional pacemakers and does not create a visible lump under the skin. Advancements in battery and computer technology have made the Micra next-generation pacemaker smarter, allowing cardiologists to treat a wider range of heart conditions.

Wase explains, "So yes, pacemakers have been around f...

 Wade Demmer, R&D Vice President at Medtronic, has developed a leadless pacemaker that is implanted on the heart through a minimally invasive procedure utilizing a catheter, potentially creating fewer complications and greater access for patients who could benefit from a pacemaker. This new design is a significantly smaller, safer, and longer-lasting device than traditional pacemakers and does not create a visible lump under the skin. Advancements in battery and computer technology have made the Micra next-generation pacemaker smarter, allowing cardiologists to treat a wider range of heart conditions.

Wase explains, "So yes, pacemakers have been around f...

Dr. Vishwa Srivastava, APAC CEO of SSI, SS Innovations International, is a leader in telesurgery, using robotic surgery to extend surgical services in underserved areas. The SSI Mantra surgical robot is used for laparoscopic surgery and offers an affordable alternative to prevailing robotic solutions without compromising quality. Telesurgery has potential in remote operations and is also revolutionizing surgical training by providing real-time expert proctoring.

Vishwa explains, "My father was one of the early global pioneers in robotic cardiac surgery, and he had actually helped Intuitive Surgical back in their early days get their FDA approval. And what...

Dr. Vishwa Srivastava, APAC CEO of SSI, SS Innovations International, is a leader in telesurgery, using robotic surgery to extend surgical services in underserved areas. The SSI Mantra surgical robot is used for laparoscopic surgery and offers an affordable alternative to prevailing robotic solutions without compromising quality. Telesurgery has potential in remote operations and is also revolutionizing surgical training by providing real-time expert proctoring.

Vishwa explains, "My father was one of the early global pioneers in robotic cardiac surgery, and he had actually helped Intuitive Surgical back in their early days get their FDA approval. And what...

Vikram Ahuja, Co-Founder and CEO, and Joe Promoppatam, Co-Founder and CTO of OsseoLabs, are utilizing 3D printing and AI to advance reconstructive surgery by enabling the creation of personalized, precision-fit implants and surgical instruments. Traditional surgery has relied on standardized implants made of titanium and involves lengthy operations. The OsseoLabs approach reduces surgical planning and operating time, improving patient outcomes by achieving a better fit and enhanced bone integration through the use of advanced implant materials. AI is used to automate and accelerate the design process for these custom devices, enabling a scalable and cost-effective approach to create complex...

Vikram Ahuja, Co-Founder and CEO, and Joe Promoppatam, Co-Founder and CTO of OsseoLabs, are utilizing 3D printing and AI to advance reconstructive surgery by enabling the creation of personalized, precision-fit implants and surgical instruments. Traditional surgery has relied on standardized implants made of titanium and involves lengthy operations. The OsseoLabs approach reduces surgical planning and operating time, improving patient outcomes by achieving a better fit and enhanced bone integration through the use of advanced implant materials. AI is used to automate and accelerate the design process for these custom devices, enabling a scalable and cost-effective approach to create complex...

Trân Lê, Co-Founder and CEO of Grove AI,  was founded to automate the manual and inefficient workflows in clinical trial recruitment, patient engagement, and support. The company's AI agent, Grace, is trained on specific trial protocols and approved scripts to respond to patient questions about pre-screening, logistics, and scheduling appointments. This platform aims to increase speed and quality of participant recruitment, improve representation, and expand accessibility to clinical trials by offering support in over 19 languages and providing access to information on demand.

Trân explains, "The birth of Grove really came from my co-founder, Sohit, and his...

Trân Lê, Co-Founder and CEO of Grove AI,  was founded to automate the manual and inefficient workflows in clinical trial recruitment, patient engagement, and support. The company's AI agent, Grace, is trained on specific trial protocols and approved scripts to respond to patient questions about pre-screening, logistics, and scheduling appointments. This platform aims to increase speed and quality of participant recruitment, improve representation, and expand accessibility to clinical trials by offering support in over 19 languages and providing access to information on demand.

Trân explains, "The birth of Grove really came from my co-founder, Sohit, and his...